EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische StudieOpen Access

Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke

Xia Meng, Shuya Li, Hongguo Dai, Guozhi Lu, Weiwei Wang, Fengyuan Che, Yu Geng, Minghui Sun, Xiyan Li, Hao Li, Yongjun Wang

JAMA · 05.11.2024 · 332 (17) · 1437

DOI: 10.1001/jama.2024.14721 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 05.11.2024. Verfasst von Xia Meng und 10 weiteren Autor:innen. Beteiligte Einrichtung: China National Clinical Research Center for Neurological Diseases, Beijing. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Ischemic Stroke, Tenecteplase, Tissue Plasminogen Activator. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg/kg in Chinese patients with acute ischemic stroke (AIS) is limited.

Objective

To establish the noninferiority of tenecteplase to alteplase in patients with AIS within 4.5 hours of symptom onset. Design, Setting, and Participants The ORIGINAL study was a multicenter, active-controlled, parallel-group, randomized, open-label, blinded end point, noninferiority trial conducted between July 14, 2021, and July 14, 2023. Participants were recruited from 55 neurology clinics and stroke centers in China and were eligible if they had AIS with a National Institutes of Health Stroke Scale score of 1 to 25 with measurable neurologic deficit and were symptomatic for at least 30 minutes without significant improvement.

Interventions

Patients were randomized (1:1) within 4.5 hours of symptom onset to receive intravenous tenecteplase (0.25 mg/kg) or intravenous alteplase (0.9 mg/kg). Main Outcomes and Measures The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0 or 1 (no symptoms or no significant disability) at day 90, tested for noninferiority (risk ratio [RR] margin, 0.937). Safety end points included symptomatic intracerebral hemorrhage (per European Cooperative Acute Stroke Study III definition) and 90-day all-cause mortality.

Results

Among the 1489 patients randomized, 1465 patients were included in the full analysis set (732 in the tenecteplase group; 733 in the alteplase group) and 446 (30.4%) were female. The primary outcome occurred in 72.7% (532/732) of patients receiving tenecteplase and 70.3% (515/733) receiving alteplase (RR, 1.03 [95% CI, 0.97-1.09]; noninferiority threshold met). Symptomatic intracerebral hemorrhage occurred in 9 patients (1.2%) in each group (RR, 1.01 [95% CI, 0.37-2.70]). The 90-day mortality rate was 4.6% (34/732) in the tenecteplase group and 5.8% (43/736) in the alteplase group (RR, 0.80 [95% CI, 0.51-1.23]). Conclusions and Relevance In patients with AIS eligible for intravenous thrombolysis within 4.5 hours after stroke onset, tenecteplase was noninferior to alteplase with respect to excellent functional outcome (mRS score of 0 or 1) at 90 days and had a similar safety profile. Findings from this study support tenecteplase as a suitable alternative to alteplase in this setting. Trial Registration ClinicalTrials.gov Identifier: NCT04915729

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsIschemic StrokeTenecteplaseTissue Plasminogen ActivatorThrombolytic TherapyAgedFemaleHumansMaleMiddle AgedAged, 80 and overTreatment OutcomeInfusions, Intravenous

Substanzen

Fibrinolytic AgentsTenecteplaseTissue Plasminogen Activator

Autor:innen und Institutionen

  • China National Clinical Research Center for Neurological Diseases, Beijing.
  • Departments of Neurology and Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Linfen Central Hospital, Linfen, China.
  • Hexigten Banner Mongolian Traditional Chinese Medicine Hospital, Chifeng, China.
  • Xianyang Hospital of Yan'an University, Xianyang, China.
  • Linyi People's Hospital, Linyi, China.

Zitieren

APA

Meng, X., Li, S., Dai, H., Lu, G., Wang, W., Che, F., Geng, Y., Sun, M., Li, X., Li, H., & Wang, Y. (2024). Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke. JAMA, 332(17), 1437. https://doi.org/10.1001/jama.2024.14721

Vancouver

Meng X, Li S, Dai H, Lu G, Wang W, Che F, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke. JAMA. 2024;332(17):1437. doi:10.1001/jama.2024.14721

BibTeX
@article{Meng2024,
  author = {Meng, Xia and Li, Shuya and Dai, Hongguo and Lu, Guozhi and Wang, Weiwei and Che, Fengyuan and Geng, Yu and Sun, Minghui and Li, Xiyan and Li, Hao and Wang, Yongjun},
  title = {Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {17},
  pages = {1437},
  doi = {10.1001/jama.2024.14721}
}
Kostenlos starten →